PDF(Sci-hub)
Abstract：
Αndrogenetic alopecia (AGA) is the most common hair disorder, affecting approximately 50% of men and women. A topical lotion that contains two patented formulas (Redensyl and Sepicontrol A5), has been introduced as an alternative approach to standard therapies for AGA. Forty-four patients with AGA were randomized either to apply the active lotion or the vehicle, twice daily for 24 weeks. Subjects were evaluated at 0, 12, and 24 weeks by clinical examination, photographic documentation, quality of life evaluation (DLQI), and trichogram (anagen-to-telogen ratio). Forty-one patients, 18 males and 23 females, completed the study. Among patients receiving active treatment (n = 26), 7.7% had great improvement, 73.1% had moderate improvement, and 19.2% remained stable. The median self-assessment score increased from 4 at baseline to 6 at 24 weeks (P < .001), while the DLQI improved from 4 to 3, respectively (P < .001). The median anagen-to-telogen ratio increased from 2.25 to 4.00 to 6.02 at weeks 0, 12, and 24, respectively. No significant adverse events were reported. This new topical active blend is effective in the treatment of AGA, with high degree of patients\' satisfaction, improvement of quality of life, and an excellent safety profile. Thus, it may represent a useful alternative therapeutic approach for AGA.
摘要：
脱发(AGA)是最常见的毛发疾病,影响了大约50%的男性和女性。一种含有两种专利配方（Redensyl和SepicontrolA5）的外用乳液，已被引入作为AGA标准疗法的替代方法。44例AGA患者被随机分配使用活性洗剂或赋形剂，每天两次，共24周。在第0、12和24周通过临床检查对受试者进行评估，摄影文档,生活质量评估(DLQI)，和毛色图（生长期与睡眠原之比）。41名患者,18男23女,完成研究。在接受积极治疗的患者中（n=26），7.7%有很大改善，73.1%有中度改善,19.2%保持稳定。中位自我评估得分从基线时的4分增加到24周时的6分（P<.001），而DLQI分别从4提高到3(P<.001)。在第0周、第12周和第24周，中位生长期与静止期比值分别从2.25增加到4.00，再增加到6.02。未报告显著不良事件。这种新的局部活性混合物是有效的治疗AGA，患者满意度高，提高生活质量，和出色的安全性。因此，它可能是AGA的一种有用的替代治疗方法。
